GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.

The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News.

AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology.

The post At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer appeared first on MedCity News.

Justin Brueck, vice president of innovation and research at Endeavor Health, shared three main reasons that technology pilots end up being unsuccessful at health systems.

The post The Top 3 Reasons That Hospitals’ Tech Pilots Fail appeared first on MedCity News.

GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.

The post Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush appeared first on MedCity News.

The conference is the premier boutique healthcare investment event in the U.S. and is scheduled for May 21-22 in Chicago at the Ritz Carlton hotel.

The post There’s Still Time to Register for MedCity INVEST appeared first on MedCity News.

In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities.

The post Want to Connect with Innovative Healthcare Startups and Investors? Register for MedCity INVEST Today! appeared first on MedCity News.

The conference will be held at the Ritz Carlton hotel in Chicago May 21-22. Space is limited., so secure your spot today to attend!

The post Time is Running Out to Register for Boutique Healthcare Conference MedCity INVEST appeared first on MedCity News.

Join MedCity News and nearly 300 healthcare investors, startups, and innovative-minded executives in Chicago at the Ritz Carlton on May 21-22. Space is limited. Secure your spot today to attend!

The post Boutique Healthcare Investment Event MedCity INVEST Is Two Months Away. Register Today! appeared first on MedCity News.

MedCity INVEST 2024, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, is the ideal event to discuss healthcare funding with investors looking for investment opportunities. 

The post Don’t Miss the Best Boutique Healthcare Investment Conference — Register for MedCity INVEST Today! appeared first on MedCity News.

Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers
are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!

The post Healthcare Startups, Time is Running Out to Enter the MedCity INVEST Pitch Perfect Contest in Chicago appeared first on MedCity News.

Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!

The post Connect With More Than 50 Healthcare Startups at MedCity INVEST 2024! appeared first on MedCity News.

The conference is the premier boutique healthcare investment event in the U.S.

The post Network With More Than 50 Healthcare VC firms at MedCity INVEST 2024! appeared first on MedCity News.

Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.

The post This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source appeared first on MedCity News.

Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

The post Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing appeared first on MedCity News.

Chicago-based Rush University System for Health recently struck a partnership with Cadence — the health system is beginning an RPM pilot using the startup’s technology platform and clinicians. Rush will enroll Medicare and Medicaid patients who have one or more of the following chronic conditions: hypertension, congestive heart failure and type 2 diabetes.

The post Rush Launches Program to Scale RPM for Chronic Conditions Management appeared first on MedCity News.

CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.

The post A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes appeared first on MedCity News.

During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.

The post ASCO Recap: Multiple Myeloma Moves, ADC Advances & Brain Cancer Progress appeared first on MedCity News.

The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.

The post AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types appeared first on MedCity News.

In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.

The post How Data for ImmunoGen Drug Could Change the Way Doctors Treat Ovarian Cancer appeared first on MedCity News.

A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.

The post In Key Study, Servier Drug Delays Brain Cancer in Patients With Few Treatment Options appeared first on MedCity News.

BioNTech and OncoC4 reported Phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. Earlier this year, the German company inked a deal to share in the development of the drug in various types of solid tumors.

The post At ASCO, BioNTech Shows Encouraging Data for Drug That Led to $200M Deal appeared first on MedCity News.

Hospitals are places of healing, but they have also become sites of gun violence. A panel at the MedCity News INVEST conference discussed the ways hospitals can reduce threats and de-escalate situations before they become violent.

The post How Hospitals Are Reducing Gun Violence, Protecting Patients and Staff appeared first on MedCity News.

Multiple efforts are underway to improve cell therapies for cancer. During the MedCity News INVEST conference in Chicago, a panel discussed the future of cell therapies and what the industry doing to manage the financial risks of these new treatments.

The post Where Cell Therapies Are Going Next, and How Insurers Are Getting Ready appeared first on MedCity News.

A panel during the MedCity News INVEST conference discussed what digital health technologies need to do to demonstrate return on investment for payers, providers, and other stakeholders.

The post Health Tech Startups Show Stakeholders How Digital Solutions Can Offer ROI appeared first on MedCity News.

Healthcare startups focused on solutions for payers and hospitals as well as consumers and employers will compete in the Pitch Perfect contest at MedCity INVEST May 22-24 in Chicago. Register today!

The post Which Health Tech Startups Are Competing at MedCity INVEST? appeared first on MedCity News.

Five companies will take part in the showcase with technologies addressing mental health, care coordination, aging in place, physical therapy and more. Register for INVEST, scheduled for May 22-24, at the Ritz Carlton in Chicago!

The post MedCity INVEST Spotlight: Get Ready for the Canadian Healthcare Startup Showcase appeared first on MedCity News.

Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.

The post Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug appeared first on MedCity News.

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

The post GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers appeared first on MedCity News.

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.

The post ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more appeared first on MedCity News.

PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year.

The post PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types appeared first on MedCity News.